Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00597675
Other study ID # Pro00000163
Secondary ID
Status Completed
Phase Phase 2
First received January 4, 2008
Last updated February 27, 2018
Start date March 2007
Est. completion date June 2014

Study information

Verified date March 2017
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if mucosal peanut immunotherapy will make subjects who have peanut allergy less allergic and induce changes in their immune system.


Description:

Peanut allergy is known to cause severe anaphylactic reactions. Compared with other food allergies it tends to be more persistent and also its prevalence seems to be rising. Currently there is no proven treatment other than strict avoidance. We are attempting to decrease the risk of anaphylaxis on accidental ingestion by desensitizing subjects to peanut using peanut oral mucosal immunotherapy (OIT). We are also studying the effect of peanut OIT on the peanut specific immune response to determine if tolerance to peanut protein will develop. Children ages 1 to 18 with peanut allergy will be randomized to peanut OIT or placebo. Subjects will undergo a modified rush immunotherapy on the first day and then increase the doses at least every two weeks up to a maintenance dose of 4 grams (equivalent to about 13 peanuts). Doses will be taken daily at home except for dose increases which will be done on the research unit. Subjects will undergo a double-blind, placebo-controlled food challenge (DBPCFC) after 12 months and then be unblinded. Placebo subjects will cross over to open-label peanut OIT and undergo an identical buildup schedule up to 12 months. All subjects will then complete at least 36 months of peanut OIT therapy after which once skin prick (<5 mm) and IgE (<15 kU/L) criteria are met, they will then complete the end of study DBPCFC. Dosing will continue up to a maximum of 60 months after which even if criteria are not met, the subject will undergo the end of study DBPCFC. Outcome variables of interest include response to DBPCFC, skin prick testing, peanut specific IgE, and adverse events. These results will be compared between the start and end of peanut OIT using appropriate statistical analysis.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria:

- Subject between 1 and 18 years of age

- EITHER history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts greater than 6 months ago AND peanut specific IgE >15 kU/L

- OR history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts within the past 6 months AND peanut specific IgE > 7 kU/L

- A family that will be able to be compliant with all study visits

- All females of child bearing age must be using appropriate birth control

Exclusion Criteria:

- Subjects with a history of severe, anaphylaxis to peanut

- Medical history that would prevent a double blind placebo controlled oral food challenge (DBPCFC/OFC) to peanut

- Unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up

- Diagnosed oat allergy

- Pregnancy or lactation

Study Design


Intervention

Biological:
Peanut OIT
Defatted peanut flour ingested daily as oral mucosal immunotherapy
Placebo
Oat flour matched by weight and consistency that is ingested daily as a placebo

Locations

Country Name City State
United States University of North Carolina Chapel Hill North Carolina
United States University of Arkansas Medical Center Little Rock Arkansas

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing Treatment With Peanut OIT. After completing the peanut OIT protocol (defined as treatment with peanut OIT for at least 36-months AND a peanut-specific IgE >2 and <15 AND skin prick test is <5 mm OR a maximum of 60 months of treatment), the reaction threshold for subjects is assessed by a DBPCFC. This involves eating small increasing doses of peanut protein in a blinded fashion up to a cumulative total of 5000 mg. An identical food challenge is also performed with oat flour as a placebo. The cumulative amount of peanut protein ingested prior to the dose that causes a reaction requiring treatment is reported as the reaction threshold. 36-60 months
Secondary The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing 12 Months of Blinded Peanut OIT or Placebo Treatment. After 12 months of blinded Peanut OIT treatment, the reaction threshold for subjects is assessed by a DBPCFC. This involves eating small increasing doses of peanut protein in a blinded fashion up to a cumulative total of 4710 mg. An identical food challenge is also performed with oat flour as a placebo. The cumulative amount of peanut protein ingested prior to the dose that causes a reaction requiring treatment is reported as the reaction threshold. 12 months
Secondary The Change From Baseline Through the End of Peanut OIT Treatment in Wheal Size Diameter Following Peanut Skin Prick Testing Skin prick testing is performed by scratching the skin with a small amount of peanut and observing for redness and a raised bump called a wheal. The diameter of the wheal is measured with a ruler in mm and recorded as a measure of peanut-specific IgE and mast cell reactivity in an allergic subject. A decrease in wheal size after treatment would represent suppression of the allergic response. Baseline to end of open label phase treatment (36-60 months)
Secondary The Change From Baseline Through the End of Peanut OIT Treatment in Peanut-specific IgE in the Blood Peanut specific IgE on the surface of mast cells and basophils releases histamine when exposed to peanut causing symptoms of allergy. Free-floating peanut-specific IgE is measured from serum in the blood by an immunoCAP machine and reported in kU/L. A lower level of peanut-specific IgE could suggest a decrease in the probability of reaction for a subject who is exposed to peanut. Baseline to end of open label phase treatment (36-60 months)
Secondary The Change From Baseline Through the End of Peanut OIT Treatment in Peanut-specific IgG4 in the Blood. Peanut specific IgG4 is thought to have a protective effect for a subject when exposed to peanut possibly by interfering with IgE. Peanut-specific IgG4 is measured from serum in the blood by an immunoCAP machine and reported in mg/dL. A higher level of peanut-specific IgG4 could suggest a decrease in the probability of reaction for a subject who is exposed to peanut. Baseline to end of open label phase treatment (36-60 months)
See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Enrolling by invitation NCT04885959 - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development N/A
Recruiting NCT03974555 - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Withdrawn NCT00736112 - Food Allergy - Tubes - Adenoids (FATA) Trial N/A
Active, not recruiting NCT00298337 - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Phase 2/Phase 3
Completed NCT03693456 - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response N/A
Completed NCT00461097 - Oral Immunotherapy for Childhood Egg Allergy Phase 2
Completed NCT02606721 - Food Allergy Challenge Diagnostic Study
Active, not recruiting NCT02457416 - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut N/A
Completed NCT02825069 - Study on the Induction of Food Tolerance in Babies N/A
Completed NCT02350660 - Oral Immunotherapy for Peanut and Mammalian Meat Allergies N/A
Completed NCT01084174 - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Phase 1/Phase 2
Completed NCT00932828 - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT00578656 - An Interventional Study of Milk Allergy Phase 0
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A
Completed NCT03639337 - Colonization and Persistence Capacity of a Multi-strain Probiotics in Pediatric Food Allergy to Milk or Egg. N/A